Skip to content

Booksellers & Trade Customers: Sign up for online bulk buying at trade.atlanticbooks.com for wholesale discounts

Booksellers: Create Account on our B2B Portal for wholesale discounts

Systemic Radiotherapy With Monoclonal Antibodies: Options and Problems

by Marie-Luise Sautter-Bihl , Heiner Bihl , Michael Wannenmacher
Save 89% Save 89%
Current price ₹1,488.00
Original price ₹13,520.00
Original price ₹13,520.00
Original price ₹13,520.00
(-89%)
₹1,488.00
Current price ₹1,488.00

Ships in 1-2 Days

Free Shipping in India on orders above Rs. 500

Request Bulk Quantity Quote
+91
Book cover type: Hardcover
  • ISBN13: 9783540602095
  • Binding: Hardcover
  • Subject: Medical, Nursing and Health Sciences
  • Publisher: Springer Verlag
  • Publisher Imprint: Springer V
  • Publication Date:
  • Pages: 198
  • Original Price: USD 148.0
  • Language: English
  • Edition: N/A
  • Item Weight: 500 grams
  • BISAC Subject(s): N/A

Almost a century ago Paul Ehrlich introduced the "magic bullet" concept of targeting therapeutic agents to specific tissues in order to reduce systemic toxicity. Due to the advances in hybridoma technology in the 1980s, monoclonal antibodies (MAbs) with their exquisite affinity to tumor antigens have become powerful tools in the treatment of cancer, especially when linked to therapeutic agents such as radionuclides, drugs, toxins, or enzymes. It can now be expected that such agents will lead to new cancer treatments with high therapeutic success rates. However, there are major problems in developing this therapeutic concept to a routine treatment modality. This is partly due to factors such as heterogenous distribution of tumor antigens, insufficient blood supply of tumors, high interstitial pressure, and the large interstitial space that antibodies have to traverse. This book is focused on the development in radio immunotherapy (RIT) using radio- labeled monoclonal antibodies as tumoritoxic agents. This area of research has attracted the interest of clinicians and scientists from many different disciplines. It is now clear that the full potential of RIT can only be realized through the concerted efforts of laboratory scientists (molecular biologists, cell physiologists, chemists, radiation physicists, and biologists) and cancer clinicians in nuclear medicine, radiooncology, and internal oncology.

Trusted for over 48 years

Family Owned Company

Secure Payment

All Major Credit Cards/Debit Cards/UPI & More Accepted

New & Authentic Products

India's Largest Distributor

Need Support?

Whatsapp Us